Sensitization of lung cancer to EGFR tyrosine kinase inhibitors
Congressional District Code:
Biomedical Laboratory R&D
April 2015 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
DESCRIPTION (provided by applicant): The major limitation of lung cancer therapies that selectively target the Epidermal Growth Factor Receptor (EGFR) signaling network is the emergence of secondary drug resistance mechanisms. Currently, 40% of the cases of acquired resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) are mechanistically unexplained. However, there are still no effective therapies for Non Small Cell Lung Cancer (NSCLC) harboring the secondary EGFR mutation, T790M, wh...